Zhang Shen-Rong, Zhang Yuan-Hai, Xu Qiang, Qiu Hui-Xian, Chen Qi
Department of Pediatric Cardiology, Yuying Children's Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325027, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2009 Jun;11(6):429-32.
To study the values of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in the evaluation of cardiac function in children with congenital heart disease (CHD).
Seventy-one children with CHD were classified to two groups: congestive heart failure (CHF) (n=23 ) and non-CHF (n=48). Thirty-five age-matched normal children were used as the control group. Plasma BNP content was measured using a microparticle enzyme immunoassay (MEIA) on the AxSYM. Plasma NT-proBNP content was measured using an automated electrochemiluminescence immunoassay on a Roche Modular Analytics E170 analyzer. Echocardiographic parameters, including left ventricular end diastolic dimension index (LVEDDI) and left ventricular ejection fraction (LVEF), were measured.
Plasma BNP and NT-proBNP contents in the CHF group were significantly higher than those in the non-CHF group (P<0.01). The non-CHF group had higher plasma BNP and NT-proBNP contents than the control group (P<0.01). LogBNP and LogNT-proBNP values were negatively correlated with the LVEF in the CHF group (r=-0.64, r=-0.67 respectively, P<0.01), and they were positively correlated with the LVEDDI (r=0.58, r=0.76 respectively, P<0.01). In the non-CHF group, LogBNP and LogNT-proBNP values were not correlated with the LVEF, but a positive correlation was found between the LogNT-proBNP value and the LVEDDI (r=0.35, P<0.05). Using plasma BNP content > or =149.8 pg/mL and NT-proBNP content > or =820.1 pg/mL as cut-off values for diagnosing CHF respectively, the sensitivities were 87.0 % and 91.3% respectively, the specificities were 91.7% and 97.9% respectively, and the areas under the ROC curves were 0.935 and 0.987 respectively.
Both BNP and NT-proBNP can be useful in assessment of cardiac function and diagnosis of CHF in children with CHD. NT-proBNP appears to be more sensitive and specific in the diagnosis of CHF than BNP.
研究脑钠肽(BNP)和N末端脑钠肽原(NT-proBNP)在评估先天性心脏病(CHD)患儿心功能中的价值。
将71例CHD患儿分为两组:充血性心力衰竭(CHF)组(n = 23)和非CHF组(n = 48)。选取35例年龄匹配的正常儿童作为对照组。采用AxSYM上的微粒子酶免疫分析法(MEIA)测定血浆BNP含量。采用罗氏Modular Analytics E170分析仪上的自动电化学发光免疫分析法测定血浆NT-proBNP含量。测量超声心动图参数,包括左心室舒张末期内径指数(LVEDDI)和左心室射血分数(LVEF)。
CHF组血浆BNP和NT-proBNP含量显著高于非CHF组(P < 0.01)。非CHF组血浆BNP和NT-proBNP含量高于对照组(P < 0.01)。CHF组中,LogBNP和LogNT-proBNP值与LVEF呈负相关(r分别为-0.64、-0.67,P < 0.01),与LVEDDI呈正相关(r分别为0.58、0.76,P < 0.01)。在非CHF组中,LogBNP和LogNT-proBNP值与LVEF无相关性,但LogNT-proBNP值与LVEDDI呈正相关(r = 0.35,P < 0.05)。分别以血浆BNP含量≥149.8 pg/mL和NT-proBNP含量≥820.1 pg/mL作为诊断CHF的临界值,敏感性分别为87.0%和91.3%,特异性分别为91.7%和97.9%,ROC曲线下面积分别为0.935和0.987。
BNP和NT-proBNP均可用于评估CHD患儿的心功能及诊断CHF。NT-proBNP在诊断CHF方面似乎比BNP更敏感、更特异。